Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)

China · Delayed Price · Currency is CNY

19.68

-0.01 (-0.05%)

Aug 14, 2026, 3:00 PM CST

SHA:688298 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,012	947.38	827.92	820.16	8,768	10,169
Revenue Growth	20.88%	14.43%	0.95%	-90.65%	-13.78%	211.43%
Gross Profit	418.16	360.75	168.66	179.64	3,610	7,487
Operating Income	-412.31	-484.27	-763.4	-660.15	2,260	5,820
Net Income	-551.99	-573.6	-529.02	-397.58	2,068	4,920
Earnings Per Share	-2.91	-2.98	-2.69	-1.97	10.26	24.40
EPS Growth	-	-	-	-	-57.97%	187.12%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Overseas	779.98
China	150.58
Total	930.56

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	2,400	2,572	3,289	5,217	7,758	6,297
Total Debt	326.11	325.96	488.76	608.33	82.2	18.49
Net Cash (Debt)	2,074	2,246	2,800	4,609	7,675	6,279
Net Cash Growth	-19.28%	-19.78%	-39.24%	-39.95%	22.24%	180.61%
Net Cash Per Share	10.93	11.67	14.24	22.84	38.08	31.14

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-168.72	-193.9	-348.33	-1,646	2,996	5,204
Capital Expenditures	-287.79	-307.67	-924.09	-996.05	-1,052	-507.87
Free Cash Flow	-456.51	-501.57	-1,272	-2,642	1,944	4,696
Free Cash Flow Growth	-	-	-	-	-58.60%	182.32%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	41.33%	38.08%	20.37%	21.90%	41.18%	73.63%
Operating Margin	-40.75%	-51.12%	-92.21%	-80.49%	25.78%	57.23%
Pretax Margin	-54.64%	-61.59%	-70.70%	-49.29%	28.18%	56.74%
Profit Margin	-54.56%	-60.55%	-63.90%	-48.48%	23.58%	48.38%
FCF Margin	-45.12%	-52.94%	-153.69%	-322.09%	22.17%	46.18%

Dividends

Fiscal Year	FY 2022	FY 2021
Period Ending	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	1.667	3.679
Dividend Per Share Growth	-54.69%	47.14%
Dividend Yield	2.71%	2.89%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 14, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	-	6.27	5.62
Forward PE	-	2.00	2.00	2.00	1.94	7.66
P/FCF Ratio	-	-	-	-	6.66	5.89
PS Ratio	3.76	4.78	6.84	8.79	1.48	2.72